CEO
David Woodhouse
Employees
285
Industry
Pharmaceutical Preparation Manufacturing
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Loading...
Open
1.56
Mkt cap
129M
Volume
2.2M
High
1.57
P/E Ratio
-0.89
52-wk high
4.69
Low
1.54
Div yield
N/A
52-wk low
0.60
Portfolio Pulse from Benzinga Insights
January 19, 2024 | 1:30 pm
Portfolio Pulse from Avi Kapoor
January 09, 2024 | 6:01 pm
Portfolio Pulse from Benzinga Insights
January 02, 2024 | 5:31 pm
Portfolio Pulse from Erica Kollmann
January 02, 2024 | 5:30 pm
Portfolio Pulse from Benzinga Newsdesk
January 02, 2024 | 3:24 pm
Portfolio Pulse from Benzinga Insights
January 02, 2024 | 1:05 pm
Portfolio Pulse from Charles Gross
January 02, 2024 | 12:36 pm
Portfolio Pulse from Benzinga Insights
January 01, 2024 | 9:30 pm
Portfolio Pulse from Benzinga Insights
December 29, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Insights
November 22, 2023 | 5:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.